Madrigal Pharmaceuticals had a successful launch of its MASH drug Rezdiffra, exceeding sales expectations in the third quarter. The drug targets liver disease caused by MASH and saw a significant increase in patients. Meanwhile, Compass Pathways, a leader in developing psychedelic therapies for mental health, is laying off 30% of its staff due to delays in clinical trials. UCB’s tau-targeting antibody for Alzheimer’s showed promise in slowing disease progression, but did not meet its primary endpoint. Eli Lilly reported surprising earnings, and the latest biotech news and updates are discussed on the podcast ‘The Readout LOUD’.
Source link
Madrigal, Eli Lilly, Compass Pathways latest
